Disease Modifying Therapy for Alzheimer's & Epilepsy
Disease Modifying Therapy for Alzheimer's & Epilepsy
Extended Release Formulation of Sodium Selenate for the Treatment of Neurological and Neurodegenerative Diseases
Tags: Monash University, Australia, Healthcare & Lifesciences
This therapeutic targets neurodegenerative diseases like bvFTD and PSP by activating the PP2A enzyme, combating hyperphosphorylated tau. It's in various clinical trial stages, including phase 1 and 2 for conditions such as Alzheimer's Disease, epilepsy, traumatic brain injury, The slow-release formulation, particularly of sodium selenate, aims to modify disease progression rather than just offer symptomatic relief. Unique for being a potential disease-modifying anti-tau therapy, it is exploring orphan drug designations. Its applications extend to treating chronic drug-resistant epilepsy, marking a pioneering approach in the field.
IP Type or Form Factor: Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Pharmaceutical Engineering
